摘要
代谢综合征的临床特征是高血压、肥胖、高血糖和血脂异常这些心血管病危险因素聚集性地出现在同一个体,在人群中发病率高,并且有逐年增长的趋势。随着近年来大规模多中心随机双盲安慰剂对照临床证据的获得,代谢综合征治疗的思路已出现端倪—积极改善血糖控制,用血管紧张素转换酶抑制剂和利尿类药物有效地控制血压,采用他汀类药物调整血脂,用像雷米普利这样的血管紧张素转换酶抑制剂来减少微量蛋白尿,用高强度生活方式干预、噻唑烷二酮类药物来增强胰岛素敏感性,最终改善代谢综合征患者的预后,降低代谢综合征患者心血管疾病的发病率和死亡率。
The clinical characteristic of metabolic syndromes is a combination of such cardiovascular risk factors as hypertension, obesity, high blood glucose happening to the same individual, with high incidence among people and annual increasing tendency. In recent years, as clinical evidence of large-scale randomized, double-blind, placebo-controlled trials have been obtained and the thinking of drug intervention in metabolic syndromes has already produced the clues--positively ameliorate blood glucose control, by using angiotensin converting enzyme inhibitors (ACEI) and diuretic for blood pressure control, statin medicine adjusting blood lipid abnormality, using ramipril, angiotensin-converting enzyme inhibitor that reduces the tiny deal albuminuria, and interferes with high stress lifestyle; thiazolidinsdiones medicines increase the insulin sensitivity. It will ultimately improve progression of metabolic syndromes and lower cardiovascular morbidity and mortality.
出处
《循证医学》
CSCD
2005年第2期94-98,共5页
The Journal of Evidence-Based Medicine
